AAP
PTCT icon

Arax Advisory Partners’s PTC Therapeutics PTCT Stock Holding History

Arax Advisory Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$619K Buy
7,589
+7,231
+2,020% +$522K ﹤0.01% 1499
2026
Q1 		$25.8K Sell
358
-50
-12% -$3.54K ﹤0.01% 1980
2025
Q4 		$31K Sell
408
-7,968
-95% -$579K ﹤0.01% 1873
2025
Q3 		$514K Buy
8,376
+8,336
+20,840% +$434K 0.01% 890
2025
Q2 		$1.95K Buy
+40
New +$1.9K ﹤0.01% 2572
2025
Q1 		– Sell
-104
Closed -$4.7K – 2964
2024
Q4 		$4.7K Hold
104
– – ﹤0.01% 1760
2024
Q3 		$3.86K Hold
104
– – ﹤0.01% 1822
2024
Q2 		$3.18K Buy
+104
New +$3.37K ﹤0.01% 1800

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Arax Advisory Partners's PTCT Position: Q2 2026 in Review

Arax Advisory Partners increased its PTC Therapeutics (PTCT) stake by 2,020% in Q2 2026, buying an estimated $522K and bringing the position to 7,589 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #1499.

Arax Advisory Partners first reported a position in PTCT in Q2 2024 and has held it in 8 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Arax Advisory Partners held 7,589 shares of PTC Therapeutics worth $619K as of Q2 2026.
  • Arax Advisory Partners bought 7,231 PTC Therapeutics shares in Q2 2026, an estimated $522K.
  • PTC Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1499 holding.
  • Arax Advisory Partners first reported a position in PTC Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.